ACADIA Pharmaceuticals (ACAD) AI Stock Analysis

• Market Cap: $4.29B
• Dividend Yield: N/A
• Average Volume (3M): 1.73M
• Price to Earnings (P/E): 18.9
• Beta (1Y): 1.12
• Revenue Growth: 14.41%
• EPS Growth: 627.78%
• Country: US
• Employees: 653
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): 0.16
• Shares Outstanding: 168,712,220
• 10 Day Avg. Volume: 1,978,896
• 30 Day Avg. Volume: 1,733,677
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.68
• Enterprise Value/Revenue: 2.88
• Enterprise Value/Gross Profit: 3.13
• Enterprise Value/Ebitda: 27.59
• 1Y Price Target: $29.70
• Price Target Upside: 18.19% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 20

• Rating: 73 Outperform
• Price Target: $28.00 ▲(11.42% Upside)

ACADIA Pharmaceuticals' overall stock score reflects strong financial performance and positive earnings call insights, with robust revenue growth and strategic initiatives. The valuation is reasonable, although technical analysis is limited due to missing data. The company is well-positioned for future growth, but should monitor SG&A expenses and pipeline risks.

Positive Factors

Product Adoption

Discontinuations remain below 10%, which is very good news for continued growth for this franchise.

Sales Growth

Daybue generated $96.1M in sales, marking 14% year-over-year growth with steady increases in patient uptake and persistency.

Negative Factors

Patient Adoption Challenges

The adoption might be highest among newly diagnosed patients as existing patients and caregiver networks are often educated on risk benefit profile of Daybue from the foundation network or Facebook patient groups which might have adverse effect on the adoption for a proportion of existing patients.

Risk Assessment

There is some risk associated with the upcoming Phase 3 data for ACP-101 in Prader-Willi syndrome, which could affect investor perception.

ACADIA Pharmaceuticals Business Overview & Revenue Model

Company Description

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. The company is primarily engaged in the research and development of drugs for the treatment of conditions such as Parkinson's disease psychosis and schizophrenia. Its core product, NUPLAZID (pimavanserin), is approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis and is marketed in the United States.

How the Company Makes Money

ACADIA Pharmaceuticals generates revenue primarily through the sale of its flagship product, NUPLAZID. The company earns income from product sales to healthcare providers and pharmacies. Additionally, ACADIA may receive milestone payments and royalties from partnerships with other pharmaceutical companies involved in the development and commercialization of complementary therapies. The company also engages in research collaborations and licensing agreements that can provide additional revenue streams. Factors contributing to its earnings include the growth in demand for treatments for CNS disorders, successful marketing strategies, and potential new product approvals or expansions in indications for existing drugs.

ACADIA Pharmaceuticals Financial Statement Overview

Summary

ACADIA Pharmaceuticals shows strong financial health with consistent revenue growth, improved profitability, and positive cash flows. The balance sheet reflects stability with minimal leverage, and the overall financial performance indicates a positive outlook. Continued focus on maintaining profitability and managing debt levels will be crucial for sustaining this momentum.

Income Statement

The company has shown impressive revenue growth with a TTM (Trailing-Twelve-Months) revenue of $996.3 million, up from $957.8 million in the previous year, indicating a strong upward trajectory. The gross profit margin remains robust at approximately 92.0%, reflecting efficient cost management. Net profit margin has improved significantly, turning positive, which highlights enhanced profitability. EBIT and EBITDA margins are also positive, further emphasizing operational improvements.

Balance Sheet

ACADIA Pharmaceuticals demonstrates a healthy balance sheet with a low debt-to-equity ratio, suggesting prudent financial management. The equity ratio is high, indicating a strong reliance on equity financing. Return on Equity (ROE) is positive and improving, showcasing the company's ability to generate returns on shareholders' investments. However, the company's debt levels, while manageable, should be monitored as they have increased slightly.

Cash Flow

The company has achieved positive free cash flow, marking a significant improvement from previous years. Operating cash flow to net income ratio is healthy, suggesting effective cash management. While the free cash flow growth rate has declined slightly in the latest TTM period compared to the previous year, the overall cash flow position is solid, supporting future growth initiatives.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.02B	957.80M	726.44M	517.24M	484.14M	441.75M
Gross Profit	937.10M	875.96M	680.71M	507.07M	465.00M	421.20M
EBITDA	106.30M	100.16M	-67.83M	-221.57M	-167.09M	-286.59M
Net Income	222.16M	226.45M	-61.29M	-215.97M	-167.87M	-281.58M
Balance Sheet
Total Assets	1.23B	1.19B	748.96M	587.81M	700.12M	782.62M
Cash, Cash Equivalents and Short-Term Investments	762.00M	755.99M	438.87M	416.82M	520.71M	631.96M
Total Debt	44.60M	51.99M	57.20M	62.00M	56.13M	44.46M
Total Liabilities	403.17M	454.96M	317.20M	187.40M	159.23M	155.61M
Stockholders Equity	822.38M	732.79M	431.75M	400.41M	540.89M	627.01M
Cash Flow
Free Cash Flow	187.09M	157.20M	-23.35M	-114.03M	-126.78M	-143.75M
Operating Cash Flow	187.91M	157.72M	16.70M	-114.03M	-125.66M	-136.17M
Investing Cash Flow	-127.65M	-30.54M	32.00M	73.24M	-71.10M	192.51M
Financing Cash Flow	20.03M	6.84M	25.13M	8.20M	18.16M	81.00M

ACADIA Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 25.13
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACAD, the sentiment is Positive. The current price of 25.13 is above the 20-day moving average (MA) of 23.58, above the 50-day MA of 22.59, and above the 200-day MA of 18.65, indicating a bullish trend. The MACD of 0.80 indicates Negative momentum. The RSI at 67.96 is Neutral, neither overbought nor oversold. The STOCH value of 81.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACAD.

ACADIA Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACAD	73 Outperform	$4.29B	18.88	33.18%	―	14.41%	627.78%
MRUS	62 Neutral	$4.82B	―	-48.54%	―	59.77%	-92.92%
APLS	58 Neutral	$3.02B	―	-108.49%	―	20.02%	33.45%
Sector *	51 Neutral	$7.43B	-0.36	-45.45%	2.27%	22.98%	-2.34%
IBRX	49 Neutral	$2.33B	―	78.99%	―	4227.22%	50.80%
IMVT	45 Neutral	$2.65B	―	-77.58%	―	―	-48.38%
MLTX	41 Neutral	$3.52B	―	-40.29%	―	―	-208.46%

ACADIA Pharmaceuticals Corporate Events

Acadia Pharmaceuticals Wins Patent Case for NUPLAZID

On June 9, 2025, Acadia Pharmaceuticals announced that the U.S. Court of Appeals for the Federal Circuit upheld a previous decision by the U.S. District Court for the District of Delaware, confirming the validity of the company’s composition of matter patent for NUPLAZID® (pimavanserin). This legal victory against MSN Laboratories and its affiliate MSN Pharmaceuticals reinforces Acadia’s patent position, potentially strengthening its market position and providing assurance to stakeholders regarding the protection of its intellectual property.

The most recent analyst rating on (ACAD) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on ACADIA Pharmaceuticals stock, see the ACAD Stock Forecast page.

Acadia Pharmaceuticals Holds 2025 Annual Stockholder Meeting

On May 29, 2025, Acadia Pharmaceuticals Inc. held its 2025 Annual Meeting of Stockholders, where three Class III directors were elected to the Board of Directors to serve until the 2028 Annual Meeting. Additionally, stockholders approved the compensation of the company’s named executive officers and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (ACAD) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on ACADIA Pharmaceuticals stock, see the ACAD Stock Forecast page.

ACADIA Pharmaceuticals Wins Favorable Patent Court Ruling

On May 15, 2025, ACADIA Pharmaceuticals entered into a 12-year lease agreement for new executive office space at 210 Carnegie Center in Princeton, New Jersey, with plans for commercial, research, and development activities. The company will pay an initial annual rent of $1,899,756, with incremental increases, and is responsible for operating expenses and property taxes. Additionally, ACADIA announced a favorable court ruling on May 16, 2025, regarding its formulation patent for NUPLAZID®, securing its position against competitors Aurobindo Pharma and MSN Laboratories.

The most recent analyst rating on (ACAD) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on ACADIA Pharmaceuticals stock, see the ACAD Stock Forecast page.